The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

Through the power of strategic, well-built partnerships, CVS Health helps employees earn degrees — and at no cost to them.

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, ...

Advocates have claimed that CVS’s refusal to cover Yeztugo violates the Affordable Care Act (ACA), which requires insurers to ...

Primary care physicians and the state Senate’s health care point person are questioning a proposed partnership between Mass ...

Creagh Milford, D.O., MPH, president of retail health for CVS, told Fierce Healthcare in an interview that while the national average wait time for a primary care visit is about 26 days, when he ...

It’s time for a wellness check at CVS Health. Shares of the company are down more than 20% this year as it grapples with higher-than-expected medical costs in its insurance unit and pharmacy ...

CVS Health's troubles haven't been solely on the fundamental side. Indeed, shares have underperformed on the price charts, too, down 18% on a total return basis (price change plus dividends) so ...

CVS said it would pay $10.6 billion to acquire Oak Street Health, a primary care provider mainly for adults on Medicare Advantage. Loss of jobs ...

CVS Health CVS 0.0% (NYSE: CVS) reported its Q3 results earlier this month, with revenues and earnings beating the street estimates, and we believe that CVS stock is undervalued, as discussed below.